162 related articles for article (PubMed ID: 23538047)
1. Mutation analysis of KRAS in primary colorectal cancer and matched metastases by means of highly sensitivity molecular assay.
Miglio U; Mezzapelle R; Paganotti A; Allegrini S; Veggiani C; Antona J; Gentilli S; Monga G; Alabiso O; Boldorini R
Pathol Res Pract; 2013 Apr; 209(4):233-6. PubMed ID: 23538047
[TBL] [Abstract][Full Text] [Related]
2. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
[TBL] [Abstract][Full Text] [Related]
3. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.
Neumann J; Zeindl-Eberhart E; Kirchner T; Jung A
Pathol Res Pract; 2009; 205(12):858-62. PubMed ID: 19679400
[TBL] [Abstract][Full Text] [Related]
4. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.
Loupakis F; Pollina L; Stasi I; Ruzzo A; Scartozzi M; Santini D; Masi G; Graziano F; Cremolini C; Rulli E; Canestrari E; Funel N; Schiavon G; Petrini I; Magnani M; Tonini G; Campani D; Floriani I; Cascinu S; Falcone A
J Clin Oncol; 2009 Jun; 27(16):2622-9. PubMed ID: 19398573
[TBL] [Abstract][Full Text] [Related]
5. KRAS discordance between primary and metastatic tumor in patients with metastatic colorectal carcinoma.
Siyar Ekinci A; Demirci U; Cakmak Oksuzoglu B; Ozturk A; Esbah O; Ozatli T; Celik B; Budakoglu B; Turker I; Bal O; Turan N
J BUON; 2015; 20(1):128-35. PubMed ID: 25778307
[TBL] [Abstract][Full Text] [Related]
6. Relationship Between 18F-FDG PET/CT Scans and KRAS Mutations in Metastatic Colorectal Cancer.
Kawada K; Toda K; Nakamoto Y; Iwamoto M; Hatano E; Chen F; Hasegawa S; Togashi K; Date H; Uemoto S; Sakai Y
J Nucl Med; 2015 Sep; 56(9):1322-7. PubMed ID: 26135109
[TBL] [Abstract][Full Text] [Related]
7. KRAS and BRAF mutation analysis can be reliably performed on aspirated cytological specimens of metastatic colorectal carcinoma.
Pang NK; Nga ME; Chin SY; Ismail TM; Lim GL; Soong R; Salto-Tellez M
Cytopathology; 2011 Dec; 22(6):358-64. PubMed ID: 21029218
[TBL] [Abstract][Full Text] [Related]
8. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications.
Italiano A; Hostein I; Soubeyran I; Fabas T; Benchimol D; Evrard S; Gugenheim J; Becouarn Y; Brunet R; Fonck M; François E; Saint-Paul MC; Pedeutour F
Ann Surg Oncol; 2010 May; 17(5):1429-34. PubMed ID: 20049644
[TBL] [Abstract][Full Text] [Related]
9. Acquired KRAS mutations during progression of colorectal cancer metastases: possible implications for therapy and prognosis.
Bouchahda M; Karaboué A; Saffroy R; Innominato P; Gorden L; Guettier C; Adam R; Lévi F
Cancer Chemother Pharmacol; 2010 Aug; 66(3):605-9. PubMed ID: 20361188
[TBL] [Abstract][Full Text] [Related]
10. Impact of KRAS mutation on outcome of patients with metastatic colorectal cancer.
Chang YY; Lin JK; Lin TC; Chen WS; Jeng KJ; Yang SH; Wang HS; Lan YT; Lin CC; Liang WY; Chang SC
Hepatogastroenterology; 2014 Oct; 61(135):1946-53. PubMed ID: 25713893
[TBL] [Abstract][Full Text] [Related]
11. Comparison of KRAS genotype: therascreen assay vs. LNA-mediated qPCR clamping assay.
Chang SC; Denne J; Zhao L; Horak C; Green G; Khambata-Ford S; Bray C; Celik I; Van Cutsem E; Harbison C
Clin Colorectal Cancer; 2013 Sep; 12(3):195-203.e2. PubMed ID: 23978462
[TBL] [Abstract][Full Text] [Related]
12. High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice.
Santini D; Loupakis F; Vincenzi B; Floriani I; Stasi I; Canestrari E; Rulli E; Maltese PE; Andreoni F; Masi G; Graziano F; Baldi GG; Salvatore L; Russo A; Perrone G; Tommasino MR; Magnani M; Falcone A; Tonini G; Ruzzo A
Oncologist; 2008 Dec; 13(12):1270-5. PubMed ID: 19056857
[TBL] [Abstract][Full Text] [Related]
13. Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability.
Umeda Y; Nagasaka T; Mori Y; Sadamori H; Sun DS; Shinoura S; Yoshida R; Satoh D; Nobuoka D; Utsumi M; Yoshida K; Yagi T; Fujiwara T
J Hepatobiliary Pancreat Sci; 2013 Feb; 20(2):223-33. PubMed ID: 23010994
[TBL] [Abstract][Full Text] [Related]
14. Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma.
Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
Int J Cancer; 2014 Nov; 135(9):2215-22. PubMed ID: 24659028
[TBL] [Abstract][Full Text] [Related]
15. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
16. [Correlation between KRAS mutations and clinicopathologic features in colorectal carcinomas].
Gao J; Zhang J; Lu T; Li XY; Jia N; Liang ZY
Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):595-8. PubMed ID: 23157826
[TBL] [Abstract][Full Text] [Related]
17. KRAS mutant allele-specific imbalance (MASI) assessment in routine samples of patients with metastatic colorectal cancer.
Malapelle U; Sgariglia R; De Stefano A; Bellevicine C; Vigliar E; de Biase D; Sepe R; Pallante P; Carlomagno C; Tallini G; Troncone G
J Clin Pathol; 2015 Apr; 68(4):265-9. PubMed ID: 25609577
[TBL] [Abstract][Full Text] [Related]
18. Detection of KRAS mutations in colorectal cancer with Fast COLD-PCR.
Carotenuto P; Roma C; Cozzolino S; Fenizia F; Rachiglio AM; Tatangelo F; Iannaccone A; Baron L; Botti G; Normanno N
Int J Oncol; 2012 Feb; 40(2):378-84. PubMed ID: 21971641
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneity of KRAS status may explain the subset of discordant KRAS status between primary and metastatic colorectal cancer.
Watanabe T; Kobunai T; Yamamoto Y; Matsuda K; Ishihara S; Nozawa K; Iinuma H; Shibuya H; Eshima K
Dis Colon Rectum; 2011 Sep; 54(9):1170-8. PubMed ID: 21825899
[TBL] [Abstract][Full Text] [Related]
20. Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status.
Modest DP; Stintzing S; Laubender RP; Neumann J; Jung A; Giessen C; Haas M; Aubele P; Schulz C; Boeck S; Stemmler HJ; Kirchner T; Heinemann V
Anticancer Drugs; 2011 Oct; 22(9):913-8. PubMed ID: 21795973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]